Labetuzumab govitecan
Based on 1 Customer Validation
Labetuzumab govitecan (IMMU 130) is an Anti-CEACAM5/SN-38 antibody-drug conjugate (ADC). Labetuzumab govitecan consists of the antibody Labetuzumab, SN-38, and a pH-sensitive Linker. Labetuzumab govitecan can be used for research of cancers, such as colorectal cancer.
For research use only. We do not sell to patients.
- Purity: 96.26%
- CAS No.: 1469876-18-3
- Molecular Weight:154000 (average)
-
Storage:
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Labetuzumab govitecan (25 mg/kg, i.p., twice weekly for 4 weeks) prolongs median survival of sc LS174T Xenograft in nude mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:sc LS174T Xenograft in nude mice
-
Dosage:25 mg/kg
-
Administration:i.p. twice weekly for 4 weeks
-
Result:Prolonged median survival.
-
Animal Model:LS174T tumor xenograft model in nude mice (PK assay)
-
Dosage:0.25 mg
-
Administration:i.v.
-
Result:T1/2: 112.5 h; Cmax: 115 μg/mL; MRT: 147 h.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1469876-18-3
-
Appearance Liquid
-
Molecular Weight 154000 (average)
-
Color Colorless to light yellow
-
SMILES
[Labetuzumab govitecan]
-
Synonyms
IMMU 130; hMN-14-SN-38
-
Shipping
Shipping with dry ice.
-
Storage
-80°C, protect from light
Purity & Documentation
-
Data Sheet (268 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Dotan E, et al. Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. J Clin Oncol. 2017 Oct 10;35(29):3338-3346. [Content Brief]
[2]. Govindan SV, et al. Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug. Mol Pharm. 2015 Jun 1;12(6):1836-47. [Content Brief]
[3]. Criscitiello C,et al. Antibody-drug conjugates in solid tumors: a look into novel targets. J Hematol Oncol. 2021 Jan 28;14(1):20. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Labetuzumab govitecan Related Classifications
HY-P99681 Related Classifications
Powered by Bioz